Molecular Oncology
Volume 4, Issue 3 , Pages 284-300, June 2010

Molecular basis for therapy resistance

  • Per E. Lønning

      Affiliations

    • Section of Oncology, Institute of Medicine, University of Bergen, Norway
    • Department of Oncology, Haukeland University Hospital, Bergen, Norway
    • Corresponding Author InformationDepartment of Oncology, Haukeland University Hospital, Bergen, Norway. Tel.: +47 55975000.

Received 8 March 2010; received in revised form 16 April 2010; accepted 16 April 2010. published online 03 May 2010.

Abstract 

Chemoresistance remains the main reason for therapeutic failure in breast cancer as well as most other solid tumours. While gene expression profiles related to prognosis have been developed, so far use of such signatures as well as single markers has been of limited value predicting drug resistance. Novel technologies, in particular with regard to high through-put sequencing holds great promises for future identification of the key “driver” mechanisms guiding chemosensitivity versus resistance in breast cancer as well as other malignant conditions.

Keywords: Breast cancer, Chemoresistance, p53, Microarray, Prediction

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1574-7891(10)00027-X

doi:10.1016/j.molonc.2010.04.005

Molecular Oncology
Volume 4, Issue 3 , Pages 284-300, June 2010

Article Tools

* Image Usage & Resolution